Clinical Trial

Remote Anxiety Management for ICS-resistant Asthma Study

Study acronym: RAMICS
Recruiting
View on ClinicalTrials.gov →
Summary
This study, the Remote Anxiety Management for ICS-resistant Asthma Study (RAMICS), explores strategies to improve medication adherence and anxiety management in asthma patients who are resistant to using inhaled corticosteroids (ICS) due to anxiety. Asthma is a chronic respiratory disease affecting millions worldwide, and ICS therapy is essential for controlling symptoms and preventing severe exacerbations. However, many patients struggle with adherence, especially those with anxiety about ICS side effects. RAMICS is a multicenter, open-label, randomized controlled trial designed to evaluate the effectiveness of personalized telephone-based interventions, including medication education, progressive muscle relaxation (PMR), motivational interviewing (MI), and lung rehabilitation guidance. The study will enroll 216 adult asthma patients with poor ICS adherence and clinically significant anxiety. Participants will be randomized into two groups: the intervention group, receiving weekly telephone sessions, and the control group, receiving standard follow-up calls. The study aims to assess improvements in ICS adherence, reductions in anxiety and depression, better asthma symptom control, and enhanced quality of life. Outcomes will be evaluated immediately after the 8-week intervention and during a 3-month follow-up. By addressing both psychological and medication adherence challenges, this research aims to provide practical solutions for improving asthma management.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-06-30 -> 2027-02-28 2026-06-19
minor Completion pushed: 2026-06-30 -> 2027-06-30 2026-06-19
Trial Details
NCT Number NCT06732141
Lead Sponsor First Affiliated Hospital of Ningbo University
Conditions Asthma
Enrollment 216 participants
Start Date 2024-12-13
Primary Completion 2027-02-28 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-18